Edition:
India

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

3.88USD
23 Oct 2020
Change (% chg)

$-0.01 (-0.26%)
Prev Close
$3.89
Open
$3.92
Day's High
$3.95
Day's Low
$3.86
Volume
35,693
Avg. Vol
206,824
52-wk High
$7.75
52-wk Low
$2.90

Summary

Name Age Since Current Position

David Stack

69 2014 Independent Chairman of the Board

Mark Fitzpatrick

57 2019 President, Chief Financial Officer

Raj Kannan

56 2019 Chief Executive Officer, Director

anand Varadan

53 2020 Executive Vice President, Chief Commercial Officer

William Ludlam

55 2017 Senior Vice President - Clinical Development and Medical Affairs

Drew Enamait

45 2016 Vice President, Finance and Administration, Principal Accounting Officer

Lee Giguere

40 2019 Vice President, General Counsel, Secretary

Roni Mamluk

53 2017 Director

Todd Foley

48 2008 Independent Director

Bard Geesaman

52 2004 Independent Director

Scott Minick

68 2007 Independent Director

John Scarlett

69 2015 Independent Director

John Thero

59 2015 Independent Director

Ashley Robinson

IR Contact Officer

Biographies

Name Description

David Stack

Mr. David M. Stack serves as Independent Chairman of the Board of the Company. He joined our Board of Directors in November 2014 as Chairman. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Mr. Stack was a Managing Director of MPM from 2005 to March 2017. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company (NASDAQ: MDCO). Previously, Mr. Stack was President and General Manager at Innovex, Inc. (OTCMKTS: INVX). He was Vice President, Business Development/Marketing at Immunomedics, Inc. (NASDAQ: IMMU) from 1993 until 1995. Prior to that, Mr. Stack was with Roche Laboratories (ETR: RHO5) from 1981 until 1993, where he eventually served as Director of Business Development and Planning for Infectious Disease, Oncology, and Virology and was the Therapeutic World Leader for Infectious Disease. Mr. Stack currently serves on boards of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Amarin Corporation plc (NASDAQ: AMRN), or Amarin, and Prognos AI. Mr. Stack received his B.S. from Albany College of Pharmacy and a B.S. from Siena College.

Mark Fitzpatrick

Mr. Mark J. Fitzpatrick is no longer serves as President, Chief Financial Officer of the Company effective 6/30/2021. He has been our President since October 2016 and previously served as our Chief Executive Officer and a member of our Board of Directors from October 2016 to June 2019 and Chief Financial Officer from June 2015 to October 2016. Prior to joining us, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., a biopharmaceutical company specializing in the treatment of rare diseases, from May 2011 to June 2015. He also held the position of Chief Financial Officer at Proteon Therapeutics, Inc., RenaMed Biologics, Inc., Dynogen Pharmaceuticals, Inc., WorldStreet Corporation, and Diacrin, Inc., and has more than 25 years of financial management experience in both public and private companies. Mr. Fitzpatrick began his professional career at Arthur Andersen LLP. Mr. Fitzpatrick received his B.S. in Accounting from Boston College in 1984 and earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987.

Raj Kannan

Mr. Raj Kannan is Chief Executive Officer, Director of the Company. He became our Chief Executive Officer and joined our Board of Directors on June 17, 2019. Mr. Kannan joined our company from Kiniksa Pharmaceuticals, Ltd. (“Kiniksa”) (NASDAQ: KNSA) where he worked since July 2018 as Chief Commercial Officer. In that role, he was responsible for building and leading the company’s commercial operations, including sales, marketing, business analytics, and market access functions. Prior to Kiniksa, Mr. Kannan served as the Global Head of the Neurology and Immunology (“N&I”) business franchise at Merck KGaA, where he was responsible for $2 billion in annual revenues. In that role, he successfully led the launch of Mavenclad, an oral small molecule in multiple sclerosis. He also chaired the N&I franchise leadership team that was responsible for advancing the immunology pipeline assets, prioritizing the portfolio mix, and allocating resources across development assets. Prior to Merck KGaA, Mr. Kannan spent ten years at Boehringer Ingelheim (“Boehringer”) in roles of increasing responsibility in the U.S., Canada, and in Germany, including the role of Global Marketing Head of the Cardiovascular Franchise where he was responsible for over $3.5 billion in annual revenues. Before Boehringer, he worked for almost ten years at Merck and Co. in various roles from field sales to senior marketing manager in the U.S. Mr. Kannan has led or supported multiple successful launches across therapeutic areas both in the U.S. and globally. Mr. Kannan received a B.S. in chemistry from the University of Madras, as well as an M.B.A. from East Carolina University.

anand Varadan

Mr. anand Varadan serves as Executive Vice President, Chief Commercial Officer of the Company since April 22, 2020 and previously served as our Chief Commercial Officer from August 2015 to June 2016. Most recently, Mr. Varadan provided commercial and strategic consultancy services to the Company as well as a variety of other biotech companies and investors through his consulting firm, Ignition Insights, LLC, which he has operated since June 2016. From June 2018 to July 2019, Mr. Varadan served as Executive Vice President, Chief Commercial Officer of Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), an oncology-focused pharmaceutical company. From January 1999 to July 2015, he served in a progression of commercial leadership and general management roles at Amgen Inc. (NASDAQ: AMGN), a biopharmaceutical company, including Vice President, Inflammation and Nephrology Business Unit from April 2014 to July 2015 and Vice President/General Manager, Amgen Canada from September 2011 to April 2014. Prior to Amgen, Mr. Varadan was a brand manager at Procter and Gamble Company (NYSE: PG). Mr. Varadan received an M.B.A. from the Simon Business School at the University of Rochester and a B.A. in Zoology from The George Washington University.

William Ludlam

Dr. William Ludlam, M.D., Ph. D. is Senior Vice President, Clinical Development and Medical Affairs of the Company since January 2017, and has served the Company in roles of increasing responsibility since August 2015. Prior to joining us, he served in various roles culminating in the position of Senior Medical Director of Novartis AG (NYSE: NVS), a multinational pharmaceutical company, from March 2012 to August 2015. Dr. Ludlam also founded and served as Medical Director of the Seattle Pituitary Center at the Swedish Medical Center and the Pituitary Unit at the Oregon Health & Sciences University in Portland, Oregon. Dr. Ludlam received his M.D. and Ph.D. (Developmental Neuroscience) from the Albert Einstein College of Medicine of Yeshiva University in 1995, and a B.S. in Chemistry from Whittier College in 1986.

Drew Enamait

Mr. Drew Enamait serves as Vice President, Finance and Administration, Principal Accounting Officer of the Company since November 10, 2016. Previously, Mr. Enamait served as the Company’s Corporate Controller since October 2015. Prior to joining the Company, he served in various roles of increasing responsibility culminating in the position of Senior Controller, of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a public medical device company, from April 2008 to October 2015. Mr. Enamait also served as a business unit Finance Director and the Manager of Internal Audit at Thermo Fisher Scientific, Inc. (NYSE: TMO). Mr. Enamait began his professional career at Arthur Andersen LLP. Mr. Enamait received his B.S. in Accountancy, minor in Law from Bentley College in 1996 and earned a Certified Public Accountant certificate in the State of Connecticut in 1999.

Lee Giguere

Mr. Lee G. Giguere serves as Vice President, General Counsel, Secretary of the Company. Prior to joining the Company, he served as Deputy General Counsel and Assistant Secretary from July 2018 to September 2019 and Associate General Counsel and Assistant Secretary from September 2016 to July 2018 of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), an oncology-focused pharmaceutical company. Prior to joining Karyopharm Therapeutics Inc., Mr. Giguere was Senior Securities and Governance Counsel at Boston Scientific Corporation (NYSE: BSX), a Fortune 500 medical device company. Mr. Giguere began his professional career in the business law department of Goodwin Procter LLP where he concentrated his practice on representing public companies in connection with securities law and corporate governance matters and corporate finance transactions. Mr. Giguere received his B.S. in Finance from Northeastern University and his J.D. from Northeastern University School of Law.

Roni Mamluk

Dr. Roni Mamluk, Ph.D., is Director of the Company since June 15, 2017. Dr. Mamluk currently serves as chief executive officer of Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. She served as our Chief Development Officer from March 2015 to March 2017 and has served as a director of Chiasma (Israel) Ltd. since April 2017. Dr. Mamluk served as our Chief Executive Officer from April 2013 to March 2015 and held various roles in the Company from 2006 to April 2013, including Chief Operating Officer and Vice President, Research and Development. She also served as a member of our Board of Directors from April 2013 to March 2015. Prior to joining us, Dr. Mamluk established and led nonclinical research and development at Adnexus Therapeutics, Inc. Dr. Mamluk received her B.A. and Ph.D. from the Hebrew University. She completed her post-doctoral fellowship at Children’s Hospital/Harvard Medical School in the field of angiogenesis.

Todd Foley

Mr. Todd Foley serves as Independent Director of the Company. Mr. Foley joined our Board of Directors in May 2008. Mr. Foley is a managing director with MPM Capital, a venture capital firm, or MPM, which he joined in 1999. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. At MPM, Mr. Foley focuses on biotech investments and serves on a number of MPM portfolio company boards, including Rhythm Therapeutics (NASDAQ: RYTM), Repare Therapeutics, Inc., CODA Biotherapeutics Inc., Entrada Therapeutics, Inc., Iconic Therapeutics, Inc. and Tetherex Pharmaceuticals, Inc. Mr. Foley previously served on the boards of Celladon Corporation from 2012 to 2014, Proteon Therapeutics, Inc. from 2012 to 2014 and Zalicus, Inc. from 2009 to 2013. He also manages MPM’s strategic investment relationship with Novartis (NYSE: NVS), which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology, or MIT, and an M.B.A. from Harvard Business School.

Bard Geesaman

Dr. Bard J. Geesaman M.D. Ph.D. serves as Independent Director of the Company. Dr. Geesaman joined our Board of Directors in 2004. Dr. Geesaman was at MPM Capital for over a decade before leaving in December 2018. He has broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel. Prior to joining MPM, Dr. Geesaman founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company’s acquisition. After Catalyst, Dr. Geesaman joined Centagenetix, an MPM-founded company exploring the genetics of successful aging. In 2006, Dr. Geesaman joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan which listed on the Tokyo Mothers exchange in March 2017. Dr. Geesaman is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Dr. Geesaman is passionate about innovation in health care, and in 2008 took a two-year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation. Dr. Geesaman became board certified in Internal Medicine in 2000, after completing a Clinical Fellowship at the Massachusetts General Hospital. He received his Ph.D. from MIT, an M.D. from Harvard Medical School and a B.S. from University of California, Berkeley.

Scott Minick

Mr. Scott Minick is an Independent Director of the Company. He joined our Board of Directors in October 2007. From January 2010 to March 2015, Mr. Minick served as President and Chief Executive Officer of BIND Therapeutics, Inc. (NASDAQ: BIND), or BIND, a biopharmaceutical company. From 1998 to 2010, Mr. Minick was Managing Director of ARCH Venture Partners, or ARCH, and from 2010 to the present he has been Venture Partner of ARCH, where he was instrumental in the startup, development and financing of numerous ARCH portfolio companies, including BIND and Chiasma. From 1995 to 1998, Mr. Minick was Director, President and Chief Operating Officer of SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU), a biopharmaceutical company that was acquired by ALZA Corporation. Mr. Minick was formerly an executive at Baxter International, Inc. (NYSE: BAX) and Eli Lilly & Company (NYSE: LLY). He serves as a member of the board of directors of Alzheon, Inc. and Aira Tech Corp., served as a member of the board of directors of BIND from 2007 to 2015 and is a trustee of Beth Israel Deaconess Medical Center. Mr. Minick received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University, and a B.A. from the University of California, San Diego.

John Scarlett

Dr. John A. Scarlett, M.D. is an Independent Director of the Company. Dr. Scarlett joined our Board of Directors in February 2015. Dr. Scarlett has been Chief Executive Officer and director of Geron Corporation (NASDAQ: GERN), a biotechnology company, since September 2011 and President since January 2012 and was appointed to Chairman of the Board in December 2018. Previously, he was the President and Chief Executive Officer of Proteolix, Inc., a biotechnology company that merged with Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) in October 2009, and a founder and Chief Executive Officer of Tercica, Inc. (NASDAQ: TRCA), which was acquired by Ipsen S.A. (EPN: IPN) in 2008. From 1993 to 2001, Dr. Scarlett was also the founder and Chief Executive Officer of Sensus Drug Development Corporation, which was acquired by Pharmacia Corporation in 2001, and co-founded Covance Biotechnology Services, Inc., a contract biologics manufacturing and process development business that was acquired by Akzo Nobel’s (OTCMKTS: AKZOY) Diosynth Division in 2001. Earlier in his career, he worked for McNeil Pharmaceuticals Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), and Novo Nordisk Inc. (NYSE: NVO). Dr. Scarlett currently serves on the board of Cytomx Therapeutics, Inc. (NASDAQ: CTMX). He received his B.A. from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine. He completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and his fellowship in Endocrinology and Metabolism at the University of Colorado Health Sciences Center.

John Thero

Mr. John F. Thero, CPA is an Independent Director of the Company since November 2015. Mr. Thero has served as the President and Chief Executive Officer of Amarin, since 2014 after previously serving as President since November 2010 and initially as Chief Financial Officer. Mr. Thero also serves as a director of Amarin. Prior to Amarin, Mr. Thero was at ViaCell, Inc., where as Chief Financial Officer he helped guide the company to its successful sale to PerkinElmer (NYSE:PKI), and Abiomed, Inc. (NASDAQ:ABMD), where he held multiple positions, including Senior Vice President of Business Operations and Chief Financial Officer. Mr. Thero began his professional career at Arthur Andersen LLP. Mr. Thero received a B.A. in Economics and Accounting from The College of the Holy Cross. In 2019, Mr. Thero was awarded EY’s Entrepreneur of the Year for Life Sciences.

Ashley Robinson

Basic Compensation

Name Fiscal Year Total

David Stack

151,130

Mark Fitzpatrick

1,346,300

Raj Kannan

6,413,280

anand Varadan

1,568,720

William Ludlam

730,925

Drew Enamait

362,354

Lee Giguere

499,517

Roni Mamluk

206,307

Todd Foley

122,130

Bard Geesaman

113,130

Scott Minick

149,630

John Scarlett

130,630

John Thero

128,130

Ashley Robinson

--
As Of  31 Dec 2019